Robert W. Baird Raises Jazz Pharmaceuticals (NASDAQ:JAZZ) Price Target to $162.00

Jazz Pharmaceuticals (NASDAQ:JAZZ) had its price target increased by research analysts at Robert W. Baird from $154.00 to $162.00 in a report released on Monday,Benzinga reports. The firm presently has an “outperform” rating on the specialty pharmaceutical company’s stock. Robert W. Baird’s target price suggests a potential upside of 38.67% from the stock’s previous close.

JAZZ has been the subject of a number of other reports. TD Cowen decreased their price objective on shares of Jazz Pharmaceuticals from $200.00 to $195.00 and set a “buy” rating for the company in a report on Thursday, November 7th. JPMorgan Chase & Co. boosted their price objective on shares of Jazz Pharmaceuticals from $190.00 to $202.00 and gave the stock an “overweight” rating in a report on Monday, August 19th. StockNews.com upgraded shares of Jazz Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Thursday, August 1st. Royal Bank of Canada boosted their price objective on shares of Jazz Pharmaceuticals from $175.00 to $179.00 and gave the stock an “outperform” rating in a report on Wednesday, October 23rd. Finally, Wells Fargo & Company decreased their price objective on shares of Jazz Pharmaceuticals from $140.00 to $120.00 and set an “equal weight” rating for the company in a report on Thursday, August 1st. Three equities research analysts have rated the stock with a hold rating, twelve have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $175.53.

Jazz Pharmaceuticals Price Performance

JAZZ stock opened at $116.82 on Monday. The firm has a 50 day moving average price of $112.44 and a 200-day moving average price of $110.41. Jazz Pharmaceuticals has a 52-week low of $99.06 and a 52-week high of $134.17. The firm has a market capitalization of $7.06 billion, a price-to-earnings ratio of 16.45, a PEG ratio of 1.02 and a beta of 0.57. The company has a debt-to-equity ratio of 1.46, a quick ratio of 3.74 and a current ratio of 4.26.

Insider Buying and Selling at Jazz Pharmaceuticals

In other news, SVP Mary Elizabeth Henderson sold 1,410 shares of the firm’s stock in a transaction on Friday, September 6th. The shares were sold at an average price of $108.30, for a total transaction of $152,703.00. Following the sale, the senior vice president now directly owns 14,531 shares in the company, valued at $1,573,707.30. This trade represents a 8.85 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Neena M. Patil sold 3,700 shares of Jazz Pharmaceuticals stock in a transaction on Friday, November 8th. The shares were sold at an average price of $123.41, for a total transaction of $456,617.00. Following the transaction, the executive vice president now owns 33,048 shares in the company, valued at approximately $4,078,453.68. This trade represents a 10.07 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 6,110 shares of company stock valued at $720,160. Company insiders own 4.20% of the company’s stock.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the company. CWA Asset Management Group LLC purchased a new position in shares of Jazz Pharmaceuticals during the 3rd quarter valued at $3,197,000. Swedbank AB purchased a new position in shares of Jazz Pharmaceuticals during the 2nd quarter valued at $106,936,000. Vanguard Group Inc. lifted its stake in shares of Jazz Pharmaceuticals by 1.3% during the 1st quarter. Vanguard Group Inc. now owns 6,448,689 shares of the specialty pharmaceutical company’s stock valued at $776,551,000 after buying an additional 84,941 shares in the last quarter. Mitsubishi UFJ Trust & Banking Corp lifted its stake in shares of Jazz Pharmaceuticals by 131.9% during the 1st quarter. Mitsubishi UFJ Trust & Banking Corp now owns 73,757 shares of the specialty pharmaceutical company’s stock valued at $8,818,000 after buying an additional 41,950 shares in the last quarter. Finally, Advisors Asset Management Inc. lifted its stake in shares of Jazz Pharmaceuticals by 9.2% during the 1st quarter. Advisors Asset Management Inc. now owns 9,722 shares of the specialty pharmaceutical company’s stock valued at $1,171,000 after buying an additional 819 shares in the last quarter. Hedge funds and other institutional investors own 89.14% of the company’s stock.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.